A major Cochrane review has concluded that anti-amyloid Alzheimer’s drugs like lecanemab and donanemab produce statistically detectable but clinically trivial benefits for early-stage patients, while ...

A new class of Alzheimer’s drugs promised to be the first treatments that actually slow the disease rather than just manage ...

For many years, scientists believed that a protein called amyloid beta was the main cause of Alzheimer’s disease. This ...

Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the ...

I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the ...

Alzheimer’s disease is one of the most feared illnesses in the world. It slowly damages memory, thinking, and daily ...

Anti-amyloid drugs may not have a clinically meaningful effect in the treatment of Alzheimer's disease, a new review says. So ...

SGMC Health now offers an FDA-approved treatment option for people in the early stages of Alzheimer’s disease, giving ...

Valiltramiprosate is associated with low ARIA rates and is well tolerated in APOE ε4 homozygotes with early Alzheimer disease ...

A new systematic review of 17 clinical trials found that drugs targeting amyloid beta proteins are likely to have no ...

It's the latest in a long-running dispute over the drugs, which some view as groundbreaking, while others say they leave much ...